N onalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in the United States. 1 It is defined as a spectrum of diseases, from hepatic steatosis that can progress to nonalcoholic steatohepatitis, fibrosis, cirrhosis, and even hepatocellular carcinoma. 2 NAFLD is associated strongly with metabolic risk factors, 1 such as cardiovascular disease, 3 obesity, diabetes mellitus, 4, 5 and dyslipidemia. 6 Currently, the estimated US prevalence of NAFLD ranges from 17% to 51%, 1 and it is even more common in certain high-risk groups, such as individuals with severe obesity (90%), type 2 diabetes mellitus (69%), and older Hispanic males. [7] [8] [9] Liver biopsy remains the gold standard for diagnosing NAFLD. 1, 10 However, this procedure is invasive, with complications such as bleeding and infection, and is unreliable for quantifying steatosis owing to sampling error and variability among pathologist interpretation. 11, 12 Because of these disadvantages of liver biopsy, there is increasing interest in developing noninvasive methods to identify hepatic steatosis, including those measured by state-of-the-art imaging modalities. 1, 13 Although most commonly accessible to assess NAFLD, conventional ultrasonography is limited by operator dependency, low sensitivity and specificity, and lacks quantitative accuracy. [14] [15] [16] Computerized tomography is limited by low sensitivity for mild steatosis, radiation exposure, and inaccurate quantification of steatosis. 17 Advanced magnetic resonance imaging techniques that measure the proton density fat fraction (MRI-PDFF)-shown to correlate with histology-determined steatosis grade in adults with NAFLD 18, 19 -and MR spectroscopy have emerged as leading noninvasive modalities for steatosis quantification in NAFLD in terms of sensitivity, specificity, and reliability. 17, 20, 21 However, similar to liver biopsies, magnetic resonance imaging is expensive and not routinely accessible.
Quantitative ultrasound (QUS) is a technique that was developed to better characterize tissue microstructure by measuring fundamental acoustic parameters, including backscatter coefficient (BSC). 15 BSC is analogous (but not equal) to the qualitative echogenicity of tissue, which is used as a component for grading liver status in conventional clinical ultrasonography. As shown in several animal models but limited human prospective studies, BSC may have the potential to detect and quantify hepatic steatosis. [22] [23] [24] [25] Furthermore, several recent interlaboratory studies have shown that QUS methods in reference phantoms (see QUS protocol) and in vivo using clinical imaging scanners are highly reproducible and independent of operator and imaging system factors. 26, 27 This study was a cross-sectional analysis of a prospective cohort aimed to assess the accuracy of BSC to diagnose and quantify hepatic steatosis using MRI-PDFF as the reference. The rationale for using MRI-PDFF as a reference standard rather than a liver biopsy is that MRI-PDFF is more accurate than qualitative liver histologic assessment for quantifying liver fat, as previously shown.
28,29

Methods
Study Design and Derivation of Cohort
This was an Institutional Review Board-approved (by the University of California San Diego [UCSD] institutional review board), Health Insurance Portability and Accountability Act compliant, cross-sectional analysis of participants derived consecutively from a prospective cohort, aimed at assessing the accuracy of BSC to diagnose and quantify hepatic steatosis using MRI-PDFF as reference in participants with NAFLD (defined as MRI-PDFF ! 5%) and non-NAFLD controls (defined as MRI-PDFF < 5%). We followed Standards for Reporting of Diagnostic Accuracy guidelines in this study of QUS for the diagnostic accuracy in detecting hepatic steatosis (see Supplementary Table 1) .
Study participants were recruited at the UCSD NAFLD Translational Research Unit (principal investigator R. L.) between February 2012 and March 2014; 236 eligible study participants were screened and deemed eligible for the study, and 204 participants complied with the study protocol and received same-day QUS and MRI of the liver (see Supplementary Figure 1) . A priori, half of these participants (102) were assigned to a training group, and the other half were assigned to a validation group using stratified randomization by an experienced statistician before any assessment of diagnostic test characteristics to maintain the integrity of the data set. All participants provided written informed consent. Please see the "Inclusion and Exclusion Criteria" and "Clinical Evaluation" sections in the Supplementary Methods.
Quantitative Ultrasound Backscatter Coefficient Protocol
QUS was performed by a research physician (E. H.) using a Siemens S3000 scanner (Siemens AG, Mountain View, CA) with a direct Ultrasound Research Interface (URI) option. 30 Participants were asked to fast for 4 hours before the examination. Scanning was performed in the dorsal decubitus position with the right arm at maximum abduction. The 4C1 curved vector array transducer (1-4.5 MHz nominal) was placed 90
to the liver capsule through the right intercostal approach.
With the participant in a complete breath hold, multiple B-mode images were acquired of the right lobe of the liver area, avoiding major vasculature. The URI was enabled and 10 consecutive frames of transducer signals were recorded from the same region of the liver. Then, without changing any scanner settings, 10 consecutive frames were recorded in a well-characterized, tissuemimicking reference phantom with acoustic properties (sound speed, attenuation, backscatter coefficient) comparable with average human liver tissue ( Figure 1A) . Only the first frame was used for QUS analysis. URI data files, identified only by code numbers, were saved and then transferred to the server for analysis.
Quantitative Ultrasound Backscatter Coefficient Data Analysis
Ultrasonic pulses are transmitted by the transducer into tissue, where the energy is absorbed and scattered along its path as a result of the heterogeneous nature of tissue. A portion of the energy in the pulses is scattered back to the transducer (echoes). There, it is received, processed, and recorded to form one scan line at a time. A 2-dimensional ultrasonogram (1 frame) is formed from 128 scan lines, which is stored by the URI. Signal analysis for BSC is performed in a selected field of interest (FOI) that is drawn manually on the liver images ( Figure 1A ). One scan line for illustration is plotted as a raw radiofrequency (RF) signal as a function of depth ( Figure 1B ). The power spectra from the liver and phantom are computed ( Figure 1C ). The reference phantom spectrum is used to correct the liver spectrum for machine-dependent factors (focusing, gain, transducer pattern, transmit power, and so forth), as well as to correct for signal loss caused by attenuation with depth. The BSC then is calculated from the corrected power spectrum (see the Supplementary Methods for a more detailed description of this procedure).
The graphic user interface assembles the discrete lines of RF data to form a B-mode sonogram that the analyst uses to manually delineate a FOI within a relatively homogeneous portion of the liver (Figure 2A ). The FOI is drawn as large as possible at least 1 cm below the liver capsule, avoiding inclusion of and not below large vessels. The FOI then is subsegmented automatically into smaller overlapping regions of interest (subregions of interest), in which many local BSCs, as a function of frequency, corrected for signal attenuation, are calculated in a sequential process ( Figure 2B ), using the reference phantom methodology. 26 The BSC spectra averaged over the entire FOI are shown in Figure 3 for 2 participants, 1 participant with NAFLD (participant A: PDFF, 27.9%) and 1 non-NAFLD control (participant B: PDFF, 1.4%). These are the same participants whose B-mode ultrasonograms are shown in Figure 2 . Participant A shows a higher BSC across the entire frequency bandwidth than participant B (Figure 3 ). The BSC (1/cm-sr) in the liver varies over several orders of magnitude with increasing fat content per MRI-PDFF. For the purposes of this study, a narrow bandwidth of each spectrum (2.9-3.1 MHz) was selected, within which the average BSC was computed for each participant. Overall, BSC analysis takes approximately 1 to 2 minutes of analyst time and 5 to 10 minutes of postprocessing computer time running in the background. The analysis is performed offline on a PC or Macintosh (Apple Inc, Cupertino, Participants' spectra vary from that of the phantom as a result of different acoustic properties; thus, the reference phantom can be used to calibrate participant data and correct for total attenuation of tissue signals in the overall FOI. CA), running established programs in Matlab (MathWorks Inc, Natick, MA) with a user-friendly graphic user interface.
Magnetic Resonance Imaging Protocol
Please see the Supplementary Methods section for a description of the MRI protocol.
Statistical Analysis
A priori, before conducting data analysis, half of the 204 participants were assigned randomly to a training group, the other half was assigned to a validation group. Stratified randomization by 4 categories of MRI-PDFF was used (<4%, 4%-6%, 6%-8%, and >8% PDFF), to ensure that a full range of PDFF was present in both the training and validation groups, and that the 2 groups were comparable in the MRI-PDFF strata of interest. A receiver operating characteristic curve was computed for the BSC as a separate predictor of steatosis (as defined by MRI-PDFF dichotomized at 5%) using the training data set. The area under the receiver operator curve (AUC) and the 95% confidence intervals around them were computed. Please see the Supplementary Methods section for further details. Table 1 shows baseline demographic, physical, biochemical, and imaging characteristics of the study participants. In the training and validation groups, 40% and 38% were male (P ¼ .886); the mean age AE SD was 51 AE 17 and 49 AE 17 years (P ¼ .344); and the mean BMI AE SD was 30.9 AE 6.5 and 30.2 AE 6.1 kg/m 2 (P ¼ .533), respectively. The mean BSC (1/cm-sr) and MRI-PDFF (segments 5-8, %) in the training and validation groups were as follows: 0.026 AE 0.046 vs 0.018 AE 0.030 1/cm-sr (P ¼ .152), and 11.4% AE 9.0% vs 10.7% AE 8.2% (P ¼ .537), respectively. In both the training and validation groups, 70 of 102 participants (69%) had NAFLD by MRI-PDFF (!5%). There was no significant difference in any of these parameters between the training and validation groups. Figure 4 graphically compares QUS BSC with MRI-PDFF in both the training and validation groups combined. The Spearman rank correlation coefficient between BSC and MRI-PDFF was r ¼ 0.82 (P < .0001) in the training group, r ¼ 0.79 (P < .0001) in the validation group, and r ¼ 0.80 (P < .0001) overall. Correlation of BSC and MRI-PDFF with various metabolic parameters is provided in Supplementary Table 2 .
Results
Participant Characteristics
Correlations Between Backscatter Coefficient Versus Magnetic Resonance Imaging-Proton Density Fat Fraction and Body Mass Index in the Training and Validation Groups
Accuracy of Quantitative Ultrasound Backscatter Coefficient for the Diagnosis of Hepatic Steatosis: Magnetic Resonance Imaging-Proton Density Fat Fraction ! 5%
In the training group, BSC provided an AUC of 0.98 (95% confidence interval, 0.95-1.00; P < .0001) for the diagnosis of steatosis ( Figure 4B ). In the training group, the optimal BSC cut-off value of 0.0038 1/cm-sr provided a sensitivity of 93%, a specificity of 97%, a positive predictive value (PPV) of 99%, a negative predictive value (NPV) of 86%, and total accuracy of 94% (Table 2 ). In the validation group, the training group's cut-off value provided a sensitivity of 87%, a specificity of 91%, a PPV of 95%, a NPV of 76%, and total accuracy of 88%. We conducted sensitivity analyses to carefully examine whether the accuracy of BSC was lower in individuals with a higher BMI by stratifying the cohort into 2 groups: less than the median BMI (<31 kg/m 2 ) and the median BMI or higher (!31 kg/m 2 ). The results remained consistent and we did not find any difference in the accuracy of BSC between the 2 groups (P ¼ .37). Table 2 shows a secondary analysis of the QUS parameter, BSC, at its optimal cut-off values, and performance parameters (sensitivity, specificity, PPV, and NPV) at various MRI-PDFF thresholds (!4%, 5%, 6%, and 8%). Overall, the BSC showed robust AUCs across various MRI-PDFF thresholds. The highest AUC seen (0.98) was for BSC at a MRI-PDFF threshold of 5% or higher.
Secondary Analysis of Quantitative Ultrasound Backscatter Coefficient and Optimal Cut-Off Values at Different Magnetic Resonance Imaging-Proton Density Fat Fraction Thresholds
Discussion
In this cross-sectional analysis of a prospective cohort of adults with and without NAFLD, we show that QUS BSC is accurate in diagnosing hepatic steatosis, using MRI-PDFF as the reference. Furthermore, we found that BSC correlated strongly with the degree of hepatic steatosis (as represented by MRI-PDFF), and thus showed potential for noninvasive quantification of liver fat content. In stringent sensitivity analyses across various MRI-PDFF thresholds (!4%, 5%, 6%, and 8%), the BSC showed robust AUCs across the entire range; moreover, the optimal BSC cut-off value depended on the threshold. These findings add to the current literature in that QUS parameter outcomes have not been studied extensively in a large prospective human cohort to date for the diagnosis and quantification of liver fat. Although liver biopsy remains the gold standard for diagnosing NAFLD, the liver biopsy examination has notable limitations-including subjectivity, sampling variability, invasiveness, risk of severe pain, bleeding (1 in 500), and death (1 in 10,000)-that deem it both impractical and unreliable in population-based screening or for monitoring treatment response. 31, 32 Conventional ultrasonography has been used widely for initial screening of fatty liver because it is accessible, noninvasive, and inexpensive. 11 However, its utility is both machine-and operator-dependent, with low accuracy in the morbidly obese and poor reliability in distinguishing between steatosis and fibrosis. 33 Previous studies on the use of conventional ultrasonography for detecting fatty liver have shown sensitivities and specificities between 60% and 94% and 66% and 95%, respectively, 34, 35 showing that it does not provide a reproducible, continuous range of quantitative information for steatosis. 36 Noncontrast computerized tomography (CT) imaging is noninvasive, with good diagnostic performance in the qualitative diagnosis of steatosis, with a sensitivity of 82% and a specificity of 100% at a steatosis threshold of more than 30%. 12, 37 However, CT has poor sensitivity for mild steatosis, is unreliable for steatosis quantification, and involves radiation exposure. 17 Advanced MRI techniques can measure PDFF, which has emerged as a new standardized biomarker for assessing liver fat. 38 MRI-PDFF transcends the shortcomings of CT and older MRI techniques that are limited by T1 bias, T(2)* decay, and multifrequency signal-interference effects of protons within fat. 21, 39 MRI-PDFF correlates well with histologydetermined steatosis in adults with NAFLD. 18, 40 In a longitudinal study, MRI was more accurate and sensitive (93% sensitivity, 85% specificity) than histology in quantifying changes in steatosis over time. 29 In a randomized clinical trial studying the effect of colesevelam on liver fat, MRI-PDFF was able to detect changes in liver fat longitudinally that histology could not. 28 Despite these advantages, advanced MRI remains costly and relatively inaccessible.
The development of QUS followed various conventional ultrasonographic techniques aimed at improving diagnostic accuracy for steatosis. Please see the Supplementary Methods section for further details.
This methodology overcomes previous limitations of conventional ultrasonography because QUS parameters are estimated using a reference phantom and objective computer algorithms. Thus, the phantom reference addresses machine (transducer format, gain, dynamic range, focusing, frequency, and so forth) and operator dependencies, therefore helping to reduce both sources of variability.
The implementation of QUS requires training of an experienced sonographer in a short (<1 h) training session. Because the QUS procedures and measures are platform-independent, it can be performed on any conventional ultrasonography scanner from any manufacturer. This accessibility, along with the advantages of QUS as a noninvasive and relatively cost-effective imaging modality, improves the viability of QUS as a largescale screening and monitoring tool for the general population and for research, including clinical trials and the development of therapies. The strengths and limitations of this study are shown in the Supplementary Discussion section.
Conclusions
The primary findings of this study show that the QUS parameter BSC can diagnose and quantify hepatic steatosis accurately, using MRI-PDFF as the reference. QUS methodologies may be a promising, relatively inexpensive modality to screen the general population for fatty liver disease. The availability, cost, and accuracy of BSC outweigh the risks involved with liver biopsy. Future studies could examine the use of multiple QUS parameters on a larger cohort of participants and perform a longitudinal follow-up evaluation, include a multicenter study, or compare BSC vs liver biopsy for the diagnosis of hepatic steatosis, perhaps in a 3-way comparison with MRI-PDFF.
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Supplementary Methods
Inclusion and Exclusion Criteria
Inclusion criteria were as follows: at least 18 years of age, willing and able to complete all procedures and observations specified in the protocol, fully informed, and had signed the Informed Consent/Assent and Health Insurance Portability and Accountability Act provisions. Exclusion criteria were as follows: female participants who were pregnant or nursing, participants with contraindications to MRI (ie, pacemakers, metallic cardiac valves, surgical clips, implanted electronic infusion pumps), participants with a history of claustrophobia, and participants who could not fit inside the MR scanner (60-cm bore).
Individuals also were excluded from the study if there were potential reasons for liver disease or steatosis: chronic alcohol consumption or abuse (alcohol intake >30 g/d within 10 years, >10 g/d in the previous year), medications (including amiodarone, methotrexate, tetracyclines, valproic acid, systemic glucocorticoids, tamoxifen), infections and chronic disease (including human immunodeficiency virus, hepatitis B or C, autoimmune hepatitis, Wilson's disease, hemachromatosis, celiac, cystic fibrosis, primary sclerosing cholangitis, a-1-antitrypsin disease, hepatocellular carcinoma).
Clinical Evaluation
Participants who were included in the study underwent focused history and physical examinations at the UCSD NAFLD Translational Research Unit. The Alcohol Use Disorders Identification Test and the Skinner Lifetime Drinking Questionnaire were used, both of which are used widely for assessing alcohol intake in participants with NAFLD.
1,2 Vital signs and anthropometrics were taken, including weight, height, body mass index, and waist circumference. Biochemical testing was performed, including aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, g-glutamyl transpeptidase, albumin, total bilirubin, fasting glucose, international normalized ratio, total cholesterol, highdensity lipoprotein, low-density lipoprotein, and triglycerides.
Quantitative Ultrasound Backscatter Coefficient
The URI allows acquisition and storage of high-quality, digital, beam-formed, RF signals from the ultrasonic transducer without filtering, processing, or scan conversion, which normally are applied to produce a B-mode ultrasound image. MATLAB software (MathWorks Inc, Natick, MA) tools for the URI are available for developing and implementing experimental processing methods.
BSC is a quantitative parameter that describes the effectiveness with which the tissue scatters ultrasound energy back to the transducer. BSC is analogous (but not equal) to the echogenicity seen on the B-mode sonogram and, in general, the higher the tissue echogenicity on the sonogram, the higher the BSC, all other factors being equivalent. The numeric value of the backscatter coefficient is relative to the amount of energy that would be returned to the transducer by a perfect reflector, therefore it is a number usually much less than 1. The advantage of our method to estimate BSC is that it is independent of the operator, scanning system, and settings being used. BSC is frequency-dependent and is a fundamental physical property of tissue, therefore it varies with composition and structure of the tissue.
BSC analysis was performed by 4 research engineers following standardized and blinding procedures that could not be altered by the analysts using the research graphic user interface developed in MATLAB software deployed on the Bioacoustics Research Laboratory server (www.brl.uiuc.edu) at the University of Illinois at Urbana-Champaign. RF scan line data were stored using the URI with 16-bit resolution and a 40 MHz sampling rate in a structured data file in which time-gain compensation values are stored in the URI file header along with the position and orientation of the RF vectors.
Quantitative Ultrasound Methodology
Signal attenuation is estimated from the ultrasonic backscattered RF data using the spectral difference reference phantom method, 3 a frequency-domain method that uses the difference in the spectral amplitude at increasing depths to estimate local attenuation from ultrasonic backscatter data. Assuming that the tissue within a small region of interest is homogeneous and isotropic, the attenuation (dB/cm) of the tissue can be estimated at each frequency discrete from
where a s ðf Þ is the attenuation of the tissue sample, a r ðf Þ is the attenuation of the reference phantom, and gðf Þ is the slope of the straight line that fits the natural log ratio of tissue sample power spectrum to the reference phantom power spectrum as a function of depth.
To implement the algorithm computationally, an FOI in the B-mode image of the liver is segmented manually to avoid vessels, lesions, and organ edges. The segmented area is analyzed to yield attenuation estimates (and thereafter the backscatter coefficient), as described later. The manually drawn FOI is subdivided into many overlapping, rectangular subregions of interest, each of which yields an estimate of attenuation vs frequency. Each individual subregion of interest is subdivided into overlapping axial sections to obtain the power spectrum at different depths through the subregion of interest, which is a requirement of the spectral difference method.
The power spectrum at each depth within each subregion of interest is calculated by gating with a rectangular window, zero-padding to a length of 8192 points (at a sample frequency of 40 MHz), and computing a fast Fourier transform. Averaging the power spectra at a particular depth over all scan lines in the subregion of interest yields the power spectral estimate of the liver tissue for that depth. The same algorithm is repeated automatically on each portion of the reference phantom with the same depth as each corresponding axial section through each corresponding subregion of interest of the liver tissue to obtain the power spectral estimate of the reference phantom. After the power spectra of the participant's liver and the reference phantom are estimated at each depth, attenuation is estimated using equation 1 for the subregion of interest. Attenuation estimates from all of the subregions of interest are averaged together to obtain the mean attenuation vs frequency over the system's bandwidth of 1.7 to 4.0 MHz. In addition, the mean attenuation vs frequency curve is fit to the power law form to provide an attenuation value for an arbitrary frequency for attenuation compensation during backscatter coefficient estimation.
The size of the subregion of interest for attenuation estimation was 24 Â 24 mm, and the length of the rectangular gating function was 8.4 mm. These dimensions yield subregions of interest that are approximately 20 pulse lengths axially and laterally, as well as a gate length of 7 pulse lengths. The size of the subregion of interest and the length of the axial sections were chosen according to previous findings using simulated RF echo data. 4 The subregion of interest overlap was set to 50% in the axial and lateral directions.
The BSC estimates were obtained using the reference phantom method. 3 The BSC of the sample can be estimated by
where BSC s and BSC r are the BSCs of the sample and reference phantom, respectively; S S and S r are the power spectra for the sample and reference phantom, respectively; z is the depth. The term 10 2z½a s ðf ÞÀa r ðf Þ=10 compensates for attenuation effects; note that a s and a r are in dB/cm for this form of compensation. The assumptions for equation 2 are that the transducer surface is touching the abdominal wall of the participant and is touching the surface of the reference phantom when the scans are being performed, and that the attenuation is homogenous in the liver tissue and the reference phantom for attenuation compensation purposes.
To implement the BSC estimation algorithm, the same area that has been segmented for attenuation estimation in each image is used for BSC estimation. The analysis area is divided into 75%-overlapped subregions of interest with dimensions of 8.93 Â 8.93 mm (equivalent to 15 Â 15 wavelengths at 2.5 MHz). The power spectrum of each subregion of interest is calculated by gating with a Hanning window and computing a fast Fourier transform of each gated A-line in the subregion of interest. Averaging the power spectra over all A-lines in the subregion of interest yields the power spectral estimate of the liver sample for that subregion of interest. The same algorithm is repeated automatically on each portion of the reference phantom with the same depth as each corresponding subregion of interest of the liver tissue to obtain the power spectral estimate of the reference phantom. With the estimated power spectra of both the liver tissue and the reference phantom, the BSC of the subregion of interest can be estimated using equation 2. BSC estimates from all the subregions of interest are averaged together to obtain the mean BSC vs frequency for the manually segmented FOI over a bandwidth of 2.0 to 4.0 MHz. The lower end of the frequency range is limited to 2.0 MHz because the BSC of the reference phantom is characterized accurately down to 2.0 MHz.
Magnetic Resonance Imaging Protocol
Participants were scanned in a supine position using a 3T MR scanner (SIGNA Excite HDxt; GE Medical Systems; Milwaukee, WI) with an 8-channel torso phasedarray surface coil centered over the liver. Noncontrast axial-magnitude, MR images were obtained through the whole liver using a 2-dimensional spoiled gradientrecalled-echo sequence. A low flip angle (10 ) was used at a repetition time of more than 100 ms to minimize T1 effects. 5 Six fractional echo magnitude images were obtained at serial opposed-phase and in-phase echo times 1.15, 2.3, 3.45, 4.6, 5.75, and 6.9 ms in a single breathhold (12-24 s). Other imaging parameters included: 8-to 10-mm slice thickness, 14 to 26 slices covering the whole liver, 0-mm slice gaps, 192 Â 192 base matrix, 1 signal average, and rectangular field of view adjusted to the body habitus and breath-hold capacity.
By using a custom open-source software plug-in for Osirix (Pixmeo Co, Geneva, Switzerland) that corrects for exponential T2* decay and that incorporates a multipeak fat spectral model, 6 MRI-PDFF parametric maps were reconstructed offline from the source MR images. Circular regions of interest with a 1-cm radius were placed in each of the 4 right liver lobe segments (segments 5-8) on the PDFF maps. PDFF values were recorded for each region of interest/segment, and a final right-lobe MRI-PDFF value for each participant was obtained by averaging the values of the 4 corresponding regions of interest.
Statistical Analysis
An optimal cut-off value for QUS BSC as a predictor of steatosis was obtained, using the highest overall combination of sensitivity and specificity (Youden index). The performance of BSC at the optimal cut-off value was validated using the validation group. Secondary AUC analyses were conducted at other MRI-PDFF dichotomization thresholds of 4%, 6%, and 8%. The sample size was inadequate to complete this secondary analysis at the 7% threshold.
Results
Correlation of Backscatter Coefficient and Magnetic Resonance Imaging-Proton Density Fat Fraction With Various Metabolic Parameters
The coefficients of correlation between QUS BSC and MRI-PDFF with various metabolic parameters were as follows: with body mass index, r ¼ 0.48 and 0.50, respectively (P ¼ .737); with triglycerides, r ¼ 0.41 and 0.42, respectively (P ¼ .691); with total cholesterol, r ¼ 0.02 and 0.11, respectively (P ¼ .049); with high-density lipoprotein, r ¼ -0.25 and -0.27, respectively (P ¼ .681); and with low-density lipoprotein, r ¼ -0.02 and 0.1, respectively (P ¼ .015) (Supplementary Table 2 ).
Discussion
The hepatorenal sonographic index uses the ratio of liver and right kidney brightness. One study compared the hepatorenal sonographic index with liver biopsy in a quantitative assessment of steatosis; the hepatorenal sonographic index was found to have better correlation and sensitivity, specificity, and accuracy in patients with moderate or severe biopsy-proven steatosis. 7 However, the hepatorenal sonographic index is parameter-, operator-, and scanner-dependent; thus, hepatorenal sonographic index cut-off values are unlikely generalizable. Controlled attenuation parameter, an algorithm of US elastography, has been used to evaluate hepatic steatosis as well. 8 One study compared the use of a controlled attenuation parameter vs biopsy for diagnosing steatosis, citing AUCs of controlled attenuation parameters for 5% or greater, greater than 33%, and greater than 66% biopsy-proven steatosis as 0.79, 0.76, and 0.70, respectively. 9 
Strengths
One strength of this study was that it was a large cohort that examined the use of QUS BSC in adult human participants for the detection of hepatic steatosis. Previous studies either used fewer human participants or were based on animal models. The study design of having a training and validation group also addressed previous concerns of validation issues in the study of new imaging and diagnostic modalities for hepatic steatosis and fibrosis. 10 The large sample size of this study along with the inclusion of a wide range of PDFF added to the generalizability of our findings.
Finally, because MRI-PDFF is a standardized and quantitative biomarker for assessing steatosis, [11] [12] [13] future studies that use MRI-PDFF as a reference could be performed and then compared with this present study. Thus, our results may be generalizable to other studies that also use MRI-PDFF as a reference.
Limitations
The QUS BSC parameter in this study was compared and correlated with MRI-PDFF-derived hepatic steatosis but was not compared directly with liver biopsy. The rationale for not using a liver biopsy assessment is that it would be unethical to perform a biopsy on individuals who have normal livers (MRI-PDFF, <5%). This is an important concern because inclusion of participants both below and above the diagnostic threshold of 5% liver fat content is necessary to assess the diagnostic performance of QUS BSC. Other limitations included the crosssectional nature of the study, which limited our ability to assess whether BSC may be used to follow-up changes longitudinally. Additional QUS-derived tissue parameters may be computed using the reference phantom technique used in this study, but our analysis was limited to BSCs. In future studies, other QUS parameters may emerge as additional new biomarkers for NAFLD. Finally, our study was a single-center study, with applicants recruited from a highly specialized NAFLD research unit, leveraging from a strong hepatology-radiology collaboration at an academic institution. Although the sample size was substantial and included demographic and clinical variety, generalizability to the US population is not yet established.
